BellaSeno Appoints Tobias Grossner to Chief Medical Officer

Dr. Grossner brings strong clinical expertise in trauma surgery and regenerative medicine and has previously been working with BellaSeno as an independent consultant. In addition, Dr. Grossner has been working as a trauma surgery specialist at University Hospital Heidelberg since 2011, most recently as Senior Consultant Trauma Surgery. In 2020, he founded the SCABALLO5 Research Consortium focusing on novel biologic approaches to bone healing. The consortium currently consists of University Hospital Heidelberg, TICEBA GmbH (Germany), RehaCell (Germany), BellaSeno GmbH (Germany / Australia), and Fraunhofer IFAM Research Institute (Germany). Dr. Grossner obtained his medical degree (Dr. med.) from Ruprecht-Karls University, Heidelberg, Germany.

“We are delighted that Tobias Grossner has joined BellaSeno as Chief Medical Officer,” said Mohit Chhaya, PhD, Co-founder and CEO of BellaSeno. "His outstanding clinical track record in clinical trials, trauma surgery and regenerative medicine will be very valuable as we progress our lead program Senella in breast reconstruction through clinical development and expand our pipeline into other indication areas such as bone reconstruction. We look forward to working with Tobias and to further maturing BellaSeno to a sophisticated regenerative medicine company."

“BellaSeno has developed a leading-edge, proprietary approach for breast and bone reconstruction," said Dr. med. Tobias Grossner, CMO of BellaSeno. “Based on a well established, absorbable polymer that has proven its benefits in various healthcare applications for decades and the unique design and additive manufacturing capabilities of Bellaseno, we are creating an unparalled regenerative medicine portfolio, which will significantly improve the curative options for patients. My goal is to bring these novel products to patients who are looking for low-risk implants that ultimately result in fully natural tissues.”

About Senella^®

Senella^® is a patented porous scaffold made of absorbable Polycaprolactone (PCL) containing highly-specialized topological and design features, which act as recipients for injected fat tissue isolated with a standard liposuction procedure. The implant is designed to get absorbed over a span of two years and to provide a stable platform for the injected fat tissue to mature, adapt to its environment and stabilize. The clinical end result is a natural soft tissue – without remnants of foreign material. Senella^® therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.